Thymosin alpha 1

Thymosin Alpha-1 (TA1) from Super Human Peptides UK is a highly conserved, 28-amino acid synthetic peptide. Endogenously, it is a naturally occurring polypeptide produced in the thymus gland that plays a fundamental role in the control of immunity, tolerance, and inflammation. In laboratory research, TA1 is revered as a master immunomodulator.

Researchers utilize this peptide to study the critical bridge between the innate and adaptive immune systems. TA1 exerts its effects primarily by interacting with Toll-like receptors (TLRs) on dendritic cells, which in turn stimulates the maturation and proliferation of cytotoxic T-cells (CD8+) and helper T-cells (CD4+). Produced under GMP-compliant conditions and verified for 99% purity or higher, Thymosin Alpha-1 is a cornerstone model for advanced research into viral clearance, oncology, vaccine adjuvants, and the reversal of immune exhaustion.

• —Master Immunomodulator: Regulates the development and activation of T-cells and dendritic cells.
• —Th1 Shift: Studied for its ability to shift the immune response toward a cellular (Th1) defense against intracellular pathogens.
• —Pleiotropic Action: Exhibits broad-spectrum immune regulation, including up-regulating the expression of MHC Class I.
• —High Purity: 99% purity or higher (verified by HPLC and MS analysis).
• —Quality Standard: GMP / ISO certified manufacturing.
• —Documentation: Full Certificate of Analysis (COA) included with every batch.

• —Dendritic Cell Activation: Studying the peptide's binding to TLR9 and TLR2 to initiate the immune cascade.
• —Th1/Th2 Balance: Researching the up-regulation of Th1 cytokines (like IL-2 and IFN-gamma) and the suppression of Th2-driven autoimmune or allergic responses.
• —Viral Clearance Models: Preclinical investigation into the eradication of chronic infections, heavily modeled against Hepatitis B, Hepatitis C, and HIV.
• —Cancer Immunology: Evaluating the peptide's ability to enhance the efficacy of traditional chemotherapies by unmasking tumour cells (MHC I expression) and recruiting natural killer (NK) cells.
• —Immune Senescence: Investigating the restoration of immune function in aged animal models experiencing natural thymic involution.

Thymosin Alpha-1 was first isolated and characterized in 1977 by Dr. Allan Goldstein. Since its discovery, it has become one of the most heavily documented peptides in clinical and preclinical immunology (often studied clinically under the name Zadaxin).

Laboratory studies demonstrate that TA1 is not a simple immune "stimulant," but rather an intelligent modulator. In models of profound immunosuppression (such as severe viral load or chemotherapy-induced leukopenia), TA1 administration rapidly restores T-cell counts and triggers dendritic cells to present antigens more effectively. Conversely, in models of hyper-inflammation or sepsis, TA1 has been shown to down-regulate runaway cytokine storms by preventing apoptosis of critical immune cells.

Because it safely orchestrates the body's own defense mechanisms without causing direct toxicity, it remains a primary focus in modern immunotherapies.

• 1.Goldstein, A.L. et al., "Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide," Proceedings of the National Academy of Sciences, 1977.
• 2.Romani, L. et al., "Thymosin alpha1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling," Blood, 2004.
• 3.Garaci, E. et al., "Thymosin alpha1 in the treatment of cancer: from basic research to clinical application," International Journal of Immunopharmacology, 2000.
• 4.Camerini, R. et al., "Safety and efficacy of thymosin alpha 1," Expert Opinion on Biological Therapy, 2005.